Phase II trial results guide a new multimodal treatment approach to MIBC скачать в хорошем качестве

Phase II trial results guide a new multimodal treatment approach to MIBC

Chiara Mercinelli, MD, IRCCS San Raffaele Hospital, Milan, Italy, discusses key factors guiding patient selection for intensive multimodal therapy in muscle-invasive bladder cancer (MIBC). Immunotherapy is a cornerstone of MIBC treatment, but since not all patients respond equally and predictive biomarkers are not always available, a combination of immunotherapy and chemotherapy is often used. In particular chemotherapy regimens suited for patients who are unfit for cisplatin-based combinations. The neoadjuvant use of nivolumab and nab-paclitaxel, as studied in the Phase II NURE-Combo trial (NCT04876313), helps assess treatment response and informs decisions about the potential for bladder preservation. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties worldwide. All rights reserved.